<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6102">
  <stage>Registered</stage>
  <submitdate>28/06/2016</submitdate>
  <approvaldate>28/06/2016</approvaldate>
  <nctid>NCT02847728</nctid>
  <trial_identification>
    <studytitle>Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice</studytitle>
    <scientifictitle>Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CA209-234</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Lung Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Single Arm Design - The study encompasses a single arm design with 400 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related pneumonitis - Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related colitis- Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related hepatitis - Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related nephritis/renal dysfunction - Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related endocrinopathies - Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related rash (including toxic epidermal necrolysis) - Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of other immune-related adverse events (eg, uveitis, pancreatitis, demyelination, Guillain-Barre Syndrome, myasthenic syndrome, and encephalitis) - Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of severe infusion reactions- Melanoma</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related pneumonitis - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related colitis - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related hepatitis - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related nephritis/renal dysfunction - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related endocrinopathies - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of other immune related adverse events (eg, uveitis, pancreatitis, demyelination, Guillain-Barre Syndrome, myasthenic syndrome, and encephalitis) - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of severe infusion reactions - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence rate of and severity of immune-related rash (including toxic epidermal necrolysis), - Lung Cancer</outcome>
      <timepoint>up to nine years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events - Other nivolumab treatment-related AEs</outcome>
      <timepoint>Up to nine years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Management of Immune-related AEs:</outcome>
      <timepoint>Up to nine years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Outcomes of Immune-related AEs:</outcome>
      <timepoint>Up to nine years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival: - 1-, 2-, 3-, 4-, and 5-year overall and median survival</outcome>
      <timepoint>Up to nine years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Nivolumab treatment pattern</outcome>
      <timepoint>Up to nine years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age =18

          -  Histologically or cytologically confirmed diagnosis of melanoma (including uveal
             melanoma) or lung cancer

          -  Treatment with commercial nivolumab for the first time, alone or in combination with
             ipilimumab, for the approved indications of nivolumab within 14 days before informed
             consent for this study OR in the case where treatment has not yet been initiated,
             documentation that the treatment strategy is determined before an informed consent to
             study participation, and treatment is initiated within 28 days after informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior participation in a clinical trial within the past 4 weeks

          -  Previously treated with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies

          -  Previously treated with anti-CTLA-4 for lung cancer

          -  Current or pending participation in a clinical trial

          -  Current or pending systemic treatment for cancer other than melanoma and lung cancer

          -  Inability to comply with the study protocol

        Other protocol defined inclusion and exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Lismore</hospital>
    <hospital>Local Institution - Wagga Wagga</hospital>
    <hospital>Local Institution - Douglas</hospital>
    <hospital>Local Institution - Frankston</hospital>
    <hospital>Local Institution - Wodonga</hospital>
    <hospital>Local Institution - Subiaco</hospital>
    <postcode>2480 - Lismore</postcode>
    <postcode>2650 - Wagga Wagga</postcode>
    <postcode>04814 - Douglas</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Donau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>InnsBruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Klagenfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brasschaat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Namur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pringy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-Nancy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hesse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mecklenburg-Western Pomerania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rhineland-Palatinate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Augsburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ballenstedt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bremerhaven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Buxtehude</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kassel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Krefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lübeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Minden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Quedlinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Recklinghausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Regensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rostock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schwerin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Traunstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Tuscany</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ravenna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Bayamon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cáceres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Toledo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Ávila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Aarau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Baden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Chur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Locarno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Aberdeen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cornwall</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an observational, multicenter study in patients treated with nivolumab for the
      approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the
      United States (US). Targeted countries in the EU for study participation include Austria,
      Belgium, France, Germany, Italy, Spain, and the United Kingdom (UK). Study objectives are to
      assess the safety experience, survival, adverse event management, and outcomes of adverse
      events associated with nivolumab in routine oncology care facilities.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02847728</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact sites directly. If there in no contact information,</name>
      <address />
      <phone>Please email:</phone>
      <fax />
      <email>clinical.trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>